Table 3.
Anti-tumour effects: clinical efficacy
|
Antitumor response |
Level 1 |
Level 2 |
Level 3 |
|---|---|---|---|
| n, (Case number) | |||
|
CR |
0 |
0 |
0 |
|
PR |
0 |
0 |
1, (Case 9) |
|
SD |
1, (Case 1) |
2, (Case 4, 6) |
1, (Case 8) |
|
PD |
1, (Case 2) |
1 (Case 5) |
1, (Case 7) |
|
Not evaluable |
1, (Case 3) |
0 |
0 |
|
DCR (%) |
50 |
66.7 |
66.7 |
|
Period of follow up (day) |
|
|
|
|
Median |
120 |
87 |
83 |
| Range | 50-213 | 24-140 | 54-84 |
Modified Response Evaluation Criteria In Solid Tumors guidelines were followed to evaluate anti-tumour effects. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; DCR, disease control rate.